Zenith Drugs Limited is an Indian pharmaceutical manufacturer specializing in the production of high-quality, cost-effective formulations. Following its successful **Initial Public Offering (IPO)** in **February 2024** and subsequent listing on the **NSE Emerge** platform, the company has transitioned from a regional player into a diversified manufacturer with a growing international footprint. Zenith operates a **WHO-GMP** compliant infrastructure, serving a dual-market strategy that balances large-scale institutional government contracts with strategic contract manufacturing for global pharmaceutical leaders. --- ### **Manufacturing Infrastructure & Capacity Expansion** Zenith operates from a centralized manufacturing hub in **Indore, Madhya Pradesh**, which has recently undergone significant capital expansion to meet global regulatory standards. | Feature | Details | |:---|:---| | **Primary Location** | Muradpura (Orangpura), Indore, Madhya Pradesh | | **Certifications** | **WHO-GMP**, **Revised Schedule 'M'** (valid until **Sept 2028**), **ISO 9001:2015** | | **New Facility Status** | Commercial production commenced in **December 2024** | | **Quality Control** | **24-hour** in-house testing lab for raw materials and finished goods | | **Future Investment** | Proposed **₹25 to ₹30 crore** for further capacity augmentation | **Strategic Cephalosporin & Tablet Expansion:** The company is currently establishing a dedicated **Cephalosporin Block** at the **Mohana MPIDC Industrial Area, Indore**. This facility is designed to meet **EUGMP (European Good Manufacturing Practice)** standards, targeting oral solids, tablets, capsules, and dry injections. * **Annual Tablet Capacity:** **365 crore units** * **Annual Oral Unit Capacity:** **6.57 crore units** * **Revenue Potential:** Fully operational capacity is projected to generate **₹350 crore** in annual revenue. * **Timeline:** Commercial production for the Cephalosporin block is expected by **September 30, 2025**. --- ### **Product Portfolio & Therapeutic Specialization** Zenith manages a vast portfolio of over **250 molecules** and **780 SKUs**, covering both human healthcare and **veterinary** sectors. **Revenue Mix by Formulation:** * **Liquid Externals (44%):** Solutions for targeted relief and direct active ingredient delivery. * **Ointments/Creams (25%):** Topical treatments for dermatological conditions. * **Oral Powders (22%):** High-bioavailability formulations, including **ORS Powder**. * **Capsules (9%):** Optimized release formulations across various therapeutic categories. * **Tablets & Liquid Orals:** High-volume production of essential medicines. **Key Therapeutic Areas:** * **Antibiotics & Antifungals:** Doxycycline, Metronidazole, Clotrimazole, and Ketoconazole. * **Topical Steroids:** Clobetasol Propionate, Mometasone, and Povidone Iodine. * **Specialized Care:** **Pregabalin** (neuropathic pain) and **Cardiac/Diabetes** (new strategic entry). * **Veterinary:** **Albendazole Bolus** (1.5gm and 3gm) for livestock health. --- ### **Institutional Dominance & Market Reach** Zenith’s primary growth engine is its institutional business, acting as a registered supplier to over **10 Indian state governments** and the **Ministry of Defence**. **Major Recent Contract Wins:** * **Ministry of Defence (DGAFMS):** **₹2.00 Crore** contract and a **2-year rate contract** for Pregabalin. * **Rajasthan (RMSCL):** Multiple contracts totaling over **₹25 Crore** for dermatologicals and general medicines. * **Madhya Pradesh (MPPHCL/Animal Husbandry):** Over **₹10 Crore** in combined orders for Povidone Iodine and **3.7 million units** of Albendazole Bolus. * **Maharashtra (MMGA):** **21.45 Lacs bottles** of Paracetamol Syrup (**₹1.65 Cr**). * **Uttar Pradesh (UPMSCL):** Supply of **~1.5 Crore units** of various creams and tablets. **Geographic Footprint:** * **Domestic:** Active in **18+ states**; **Madhya Pradesh** remains the largest contributor at **24%** of revenue. * **International:** Presence in **8+ countries**, including **Costa Rica, Mauritius, Cambodia, Myanmar, Yemen, Sierra Leone, Liberia, and Bhutan**. * **Contract Manufacturing:** Trusted partner for **Ajanta Pharma**, **Micro Labs**, and **Troikaa**. --- ### **Financial Performance & Capital Structure** The company has demonstrated a consistent upward trajectory in turnover, supported by its **₹40.68 Crore IPO** (priced at **₹79 per share**). **Key Financial Metrics:** | Metric (₹ in Lakhs) | FY 2023-24 (Consolidated) | FY 2022-23 (Standalone) | |:---|:---|:---| | **Total Income** | **13,374.19** | **11,575.82** | | **Net Profit (PAT)** | **964.65** | **488.11** | | **Net Worth** | - | **1,773.20** | **Capital Allocation & Debt:** * **IPO Proceeds:** **₹35.53 Crore** transferred to Securities Premium; funds utilized for manufacturing expansion and working capital. * **Promoter Holding:** The core group (Bhupesh Soni, Sandeep Bhardwaj, and Ajay Singh Dassundi) holds **64.09%**. * **Debt Profile:** Facilities are held with **HDFC Bank**, **PNB**, and **SIDBI** (rates **8.75%–11.65%**), secured by fixed assets and personal guarantees from directors. --- ### **Strategic Growth Targets & Efficiency Mandates** Management has outlined a clear roadmap to optimize margins and leverage new capacities: * **Growth Guidance:** Target of **25% Top Line** and **15% Bottom Line** growth. * **Working Capital Optimization:** Aiming to reduce the **Debtor Collection Period to 140 days** and **Inventory Holding to 50 days**. * **Operating Leverage:** Expecting significant benefits from the **30% fixed cost** component as production scales. * **Tax Tailwinds:** Reduction in GST from **12% to 5%** on key products is expected to drive domestic volumes. --- ### **Risk Factors & Operational Challenges** Investors should monitor several regulatory and financial complexities: **1. Regulatory & Quality Oversight:** * **NSQ Reports:** The company has faced media reports regarding "Not of Standard Quality" samples. Zenith maintains it follows **CAPA (Corrective and Preventive Actions)** and remains in active communication with the **CDSCO**. * **Compliance:** Ongoing reconciliation is required for **GST Input Tax Credits** and **MSME Act** interest provisions for payments exceeding **45 days**. **2. Financial Transparency & Audit Matters:** * **IPO Fund Management:** Auditors noted that a separate bank account for IPO proceeds was not initially opened, and some funds were reallocated from corporate purposes to working capital without a formal Board resolution. * **Related Party Transactions:** A debit balance of **₹19.21 Crore** exists with **Biogenesis Corp** (a promoter-linked firm) due to ongoing trade. **3. Operational Risks:** * **Working Capital Cycles:** Government contracts often involve payment cycles exceeding **six months**, necessitating robust liquidity management. * **Input Costs:** High dependence on **APIs** makes the company vulnerable to global price volatility and currency fluctuations. * **Integration:** The commissioning of new lines has led to a **₹1.66 crore increase in depreciation**, which may weigh on short-term margins until full capacity utilization is achieved.